Alnylam receives EU marketing authorisation for hATTR amyloidosis therapy
Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization